Oral Hypoglycemic Sulfonylurea
Shortepa - 2
Glimepiride Tablets IP 2mg
Advanced 2mg Glimepiride formulation providing 24-hour glycemic control for diabetic patients requiring enhanced pancreatic insulin secretory support.
Standardized Actives
Glimepiride IP 2mg (Second-generation sulfonylurea).
Therapeutic Purpose
- Type 2 Diabetes Mellitus in patients requiring higher pancreatic beta-cell stimulation
- Combination therapy with insulin sensitizers
- Maintenance of target HbA1c in chronic diabetic management
Administration & Care
1 tablet once daily immediately before or with the first main meal.
Strip of 10 / 15 tablets in Alu-Alu blister pack. — Store below 25°C in a dry place.
Quality, Safety & Manufacturing Standards
Every batch of Aanav Healthcare formulations is manufactured under strict current Good Manufacturing Practices (cGMP) in licensed facilities in Mumbai, India. We subject all active pharmaceutical ingredients and botanical extracts to multi-stage purity, stability, and assay tests.
- Product Title
- Shortepa - 2 (Glimepiride Tablets IP 2mg)
- Therapeutic Segment
- Oral Hypoglycemic Sulfonylurea — Diabetology
- Active Formula
- Glimepiride IP 2mg (Second-generation sulfonylurea).
- Dosage & Use
- 1 tablet once daily immediately before or with the first main meal.
- Pack Packaging
- Strip of 10 / 15 tablets in Alu-Alu blister pack.
- Storage Guidelines
- Store below 25°C in a dry place.
- Regulatory Compliance
- Schedule H Prescription Drug — cGMP Certified.
Other Formulations in Diabetology
Oral Hypoglycemic Sulfonylurea
Shortepa - 1
Second-generation sulfonylurea formulation that stimulates pancreatic beta-cell insulin secretion with lower risk of severe hypoglycemia for Type 2 diabetes management.
DPP-4 Inhibitor & Biguanide Combination
Tinashe
Fixed-dose combination of a potent, selective DPP-4 inhibitor and sustained-release metformin for comprehensive 24-hour glycemic control without weight gain.
Dual Oral Anti-Diabetic Formulation
Drglim - M2
Synergistic combination targeting both pancreatic insulin secretion and peripheral insulin resistance for long-term target HbA1c maintenance.